Stanford researchers find blocking 15-PGDH restores cartilage and movement in mice
Updated
Updated · Okdiario · Apr 27
Stanford researchers find blocking 15-PGDH restores cartilage and movement in mice
6 articles · Updated · Okdiario · Apr 27
In lab tests, human knee cartilage from replacement surgery patients also showed repair signals after a week of treatment, with stiffer tissue and lower inflammation markers.
The Science study links age-related osteoarthritis to rising 15-PGDH and suggests existing cartilage cells can be reprogrammed to regenerate tissue without stem cells.
Osteoarthritis affected about 528 million people worldwide in 2019, and researchers say human trials are still needed, though a Phase 1 safety study of a 15-PGDH inhibitor showed no major concerns.
A pill to regrow cartilage is now in trials. Is this the beginning of the end for joint replacement surgery?
By reactivating old cells to repair joints, could this breakthrough accidentally awaken other age-related diseases?
With Ozempic also showing cartilage repair, will a new pill for osteoarthritis arrive too late to matter?
Breakthrough in Osteoarthritis: Blocking 15-PGDH Enzyme Regenerates Cartilage and Prevents Joint Replacement
Overview
In December 2023, researchers discovered that the enzyme 15-PGDH, which increases in aging joints, breaks down prostaglandin E2 (PGE2), a molecule essential for cartilage repair. By inhibiting 15-PGDH, PGE2 levels rise, triggering existing cartilage cells to regenerate tissue and restore joint health. This treatment reversed cartilage damage and prevented osteoarthritis after injury in mice, with similar effects seen in human cartilage samples. Early human trials showed the inhibitor is safe, and clinical studies for osteoarthritis are planned. Beyond joints, 15-PGDH inhibition also promotes muscle and nerve regeneration, offering a promising new approach to treat age-related tissue decline and reduce costly joint replacements.